{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:41Z","timestamp":1790404061969,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejca.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T22:39:56Z","timestamp":1546295996000},"page":"25-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["The real-world impact of modern treatments on the survival of patients with metastatic melanoma"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Heide","family":"\u00d8llegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Bull","family":"Aaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Hoejberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich Heide","family":"K\u00f8hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-9826","authenticated-orcid":false,"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.002_bib1","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib5","unstructured":"NCNN Clinical Practice Guidelines in Oncology - Melanoma n.d. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf (accessed May 16, 2018)."},{"key":"10.1016\/j.ejca.2018.12.002_bib6","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous Melanoma: ESMO Clinical Practice Guidelines n.d. http:\/\/www.esmo.org\/Guidelines\/Melanoma\/Cutaneous-Melanoma (accessed May 16, 2018)."},{"key":"10.1016\/j.ejca.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"Donia","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamadermatol.2015.1481","article-title":"Incidence of in situ and invasive melanoma in Denmark from 1985 through 2012 a national database study of 24 059 melanoma cases","volume":"151","author":"Maria Helvind","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib10","series-title":"Epacadostat combined with pembrolizumab in patients with unresectable or metastatic melanoma","year":"2018"},{"key":"10.1016\/j.ejca.2018.12.002_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1634\/theoncologist.2015-0478","article-title":"Sorafenib effectiveness in advanced hepatocellular carcinoma","volume":"21","author":"Sanoff","year":"2016","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2018.12.002_bib12","first-page":"1225","article-title":"Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world","volume":"140","author":"Mailankody","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line Therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2018.12.002_bib15","series-title":"Danish Follow up program for melanoma 2015 version","year":"2015"},{"key":"10.1016\/j.ejca.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1200\/JCO.2017.35.15_suppl.9524","article-title":"Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): results from a phase II study (CheckMate 172)","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T06:57:56Z","timestamp":1605941876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":19,"alternative-id":["S0959804918315387"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world impact of modern treatments on the survival of patients with metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}